East Windsor, N.J. – Aurobindo Pharma Limited has received final approval from U.S. Food and Drug Administration for its Abbreviated New Drug Application Clomipramine Hydrochloride Capsules USP, 25 mg, 50 mg, and 75 mg. Aurobindo Pharma’s Clomipramine Hydrochloride Capsules, are an AB-rated generic equivalent to the reference listed drug (RLD), Anafranil Capsules manufactured by SpecGx LLC.

Clomipramine Hydrochloride Capsules are indicated for:

• The treatment of obsessions and compulsions in patients with Obsessive-Compulsive Disorder (OCD).